Literature DB >> 2767767

In vitro induction of ciprofloxacin resistance in coagulase-negative staphylococci.

J W Hartley, B A Oppenheim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2767767     DOI： 10.1007/BF01639530

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  11 in total

1.  Resistance to ciprofloxacin.

Authors:  S T Chapman; D C Speller; D S Reeves
Journal:  Lancet       Date:  1985-07-06       Impact factor: 79.321

2.  Ciprofloxacin-resistant staphylococci.

Authors:  G M Smith; C Cashmore; M J Leyland
Journal:  Lancet       Date:  1985-10-26       Impact factor: 79.321

3.  Frequency of appearance of resistant variants to norfloxacin and nalidixic acid.

Authors:  G J Duckworth; J D Williams
Journal:  J Antimicrob Chemother       Date:  1984-05       Impact factor: 5.790

4.  The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.

Authors:  A King; K Shannon; I Phillips
Journal:  J Antimicrob Chemother       Date:  1984-04       Impact factor: 5.790

5.  A critical evaluation of nalidixic acid in urinary-tract infections.

Authors:  A R Ronald; M Turck; R G Petersdorf
Journal:  N Engl J Med       Date:  1966-11-17       Impact factor: 91.245

6.  Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.

Authors:  J E Karp; W G Merz; C Hendricksen; B Laughon; T Redden; B J Bamberger; J G Bartlett; R Saral; P J Burke
Journal:  Ann Intern Med       Date:  1987-01       Impact factor: 25.391

7.  In-vitro studies with ciprofloxacin, a new 4-quinolone compound.

Authors:  D S Reeves; M J Bywater; H A Holt; L O White
Journal:  J Antimicrob Chemother       Date:  1984-04       Impact factor: 5.790

8.  Coagulase-negative staphylococcal bacteremia in patients receiving immunosuppressive therapy.

Authors:  D J Winston; D V Dudnick; M Chapin; W G Ho; R P Gale; W J Martin
Journal:  Arch Intern Med       Date:  1983-01

9.  The activity of enoxacin against clinical bacterial isolates in comparison with that of five other agents, and factors affecting that activity.

Authors:  D S Reeves; M J Bywater; H A Holt
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

10.  Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients.

Authors:  C C Chan; B A Oppenheim; H Anderson; R Swindell; J H Scarffe
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.